ICL Group Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICL research report →
Range $5.45 – $6
Price Chart
About the company
ICL Group Ltd. is a global enterprise specializing in minerals and chemical products, operating through its various subsidiaries. Its business is structured across four primary divisions: Industrial Products, Potash, Phosphate Solutions, and Innovative Ag Solutions (IAS).
- CEO
- Elad Aharonson
- IPO
- 2005
- Employees
- 13,007
- HQ
- Tel Aviv, TA, IL
AI snapshot
Six angles, distilled from the data.
ICL is still in a corrective regime, trading below both the 50-day and 200-day averages after a long slide from the 52-week high of 6.8435. The stock is sitting near the lower end of its yearly range, which keeps the setup defensive until it can reclaim its longer-term trend.
Street sentiment is cautious but stable: 4 holds and no buy or sell ratings, with a consensus hold and a target range centered around $5.98. Recent target moves have been mixed, with Barclays cutting to $6 and Morgan Stanley trimming to $5.45 after earlier raises, suggesting limited conviction despite modest upside to targets.
The earnings pattern is uneven, with a 3-for-7 beat rate and the latest quarter missing by 9.1%. Next-year EPS is still modeled higher at 0.4548 versus 0.25 TTM, so shareholders should watch whether margin discipline can turn that forecast into a cleaner beat streak.
No discretionary insider buying or selling stands out. The recent activity is dominated by award-related grants to the CFO and EVP, plus several zero-share entries, which are compensation flows rather than trading signals.
Profitability is modest but positive, with a 30.7% gross margin, 10.74% operating margin, and 3.99% net margin. Revenue grew 3.1% year over year, while free cash flow reached $1.778 billion in 2025, giving the business solid cash generation even with ROE at 5.55%.
ICL screens as a mid-tier specialty chemicals name rather than a premium compounder, with a 9.98 P/E that is not demanding versus its cash generation. The market is valuing it more as a steady fertilizer and specialty minerals operator than a high-growth peer.
- Market Cap
- $5.27B
- P/E
- 17.13
- Fwd P/E
- 9.95
- PEG
- -1.20
- P/S
- 0.69
- P/B
- 0.86
- EV/EBITDA
- 5.23
- Div Yield
- 0.04%
- Gross Margin
- 30.71%
- Op Margin
- 10.79%
- Net Margin
- 3.99%
- ROE
- 5.09%
- ROIC
- 5.07%
Latest fiscal year · YoY change
- Revenue
- $7.15B+4.6%
- Gross Profit
- $2.19B-3.1%
- Op Income
- $703.00M
- Net Income
- $226.00M-44.5%
- EPS
- $0.18-43.8%
- OCF Growth
- -30.0%
- FCF Growth
- -80.0%
- 52W High
- $6.97
- 52W Low
- $4.07
- 50D MA
- $4.91
- 200D MA
- $5.33
- Beta
- 0.99
- RSI (14)
- 27
- Avg Volume
- 1.61M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ICL posted modest Q3 sales and EBITDA growth despite cost inflation, and management reiterated full-year guidance while pointing to improving 2027 earnings potential from ELEVATE and easing sulfur costs.· November 11, 2026
- Q3 sales rose 3% year over year to $1.9 billion, adjusted EBITDA increased 1% to $402 million, and gross margin improved 30 bps to 32.9%.
- Adjusted net income rose 2% to $126 million, or $0.10 per share; operating cash flow was $256 million and free cash flow was $66 million.
- Industrial Products was a standout, with sales up 18% to $347 million and EBITDA up nearly 50% to $100 million on stronger bromine pricing and demand.
- Potash sales rose 4% to $469 million, but EBITDA fell about 7% because of energy, transportation and FX headwinds; phosphate and growing solutions were pressured by higher sulfur and raw material costs.
- Management reaffirmed 2026 EBITDA guidance of $1.5 billion to $1.7 billion and said it is currently targeting above the midpoint, while highlighting more than $150 million of ELEVATE savings by year-end 2027.
ICL reported third-quarter 2026 sales of $1.9 billion, up 3% year over year, adjusted EBITDA of $402 million, up 1%, gross margin of 32.9%, up 30 basis points, adjusted net income of $126 million, up 2%, and adjusted EPS of $0.10. Operating cash flow was $256 million and free cash flow was $66 million; available cash resources were $2.2 billion, and net debt to adjusted EBITDA was 1.5x. By segment, Industrial Products sales were $347 million and EBITDA was $100 million; Potash sales were $469 million and EBITDA was $157 million; Phosphate Solutions sales were $589 million and EBITDA was $118 million; Growing Solutions sales were $538 million and EBITDA was $44 million. For 2026, the company reiterated consolidated EBITDA guidance of $1.5 billion to $1.7 billion and said it is currently targeting above the midpoint, potash sales volumes of 4.5 million to 4.7 million metric tons, and an adjusted tax rate of approximately 30%.
Elad Aharonson framed the quarter as a resilient performance achieved despite record raw material prices and elevated freight and logistics costs. He said the company used price increases, better mix, and operating discipline to support results, and he emphasized that the new 2027 organizational structure will sharpen focus on food, industrial, and agriculture end markets. He also expressed confidence in ELEVATE, said industry fundamentals look constructive into 2027, and repeatedly pointed to stronger conditions and growth potential as markets normalize.
Asaf Alperovitz walked through segment-level performance and noted that Industrial Products benefited from higher bromine prices, while Potash saw higher prices offset by energy, transportation, and exchange-rate headwinds. He said Phosphate Solutions generated a 20% EBITDA margin despite significantly higher raw material costs, and that Growing Solutions was managed through pricing, mix, and working capital discipline despite softer demand, especially in Brazil. On capital allocation, he highlighted $2.2 billion of available cash resources, $256 million of operating cash flow, $66 million of free cash flow, a 1.5x net debt-to-EBITDA ratio, and a dividend equal to 50% of adjusted net income, or $63 million for the quarter.
Analysts focused on how confident management is in achieving more than $150 million of ELEVATE savings in 2027 and whether the benefit would build gradually through the year. Management said it has a specific plan, is highly confident in reaching the goal, and expects savings to start showing up in Q1 2027 with a gradual ramp. Questions also centered on the 2026 EBITDA range and near-term segment drivers; management pointed to sulfur as the main Q4 headwind, said Q4 potash should not change dramatically versus Q3, and noted that weak Brazilian agriculture demand could keep pressure on the quarter.
The bullish case from the call is that ICL is still growing earnings in a difficult environment, with pricing and mix helping offset major cost inflation. Management sounded confident that sulfur costs are peaking and easing, bromine pricing is firming, and ELEVATE should add more than $150 million in annual EBITDA by the end of 2027, with more than $350 million by 2028.
The main risks discussed were high raw material, energy, and freight costs, especially sulfur, which management said will still pressure Q4 results because of inventory lag. Potash EBITDA fell year over year, phosphate fertilizer demand remained soft due to affordability, and Brazil stayed weak, so near-term results still depend on cost relief and better farm demand rather than a broad demand recovery.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.0%
- Shares Outstanding
- 1.29B
- Float Shares
- 723.13M
of shares held by institutions
224 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ICL, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Clal Insurance Enterprises Holdings Ltd | 30.18M | ▲ 10.37M |
| Vanguard Group Inc | 29.07M | ▲ 382.78K |
| Norges Bank | 21.30M | ▲ 21.30M |
| Vanguard Capital Management LLC | 21.14M | ▲ 218.55K |
| Y.D. More Investments Ltd | 19.01M | ▼ 488.79K |
| Altshuler Shaham Ltd | 16.43M | ▼ 7.55M |
| Phoenix Financial Ltd. | 14.67M | ▼ 910.78K |
| Morgan Stanley | 9.42M | ▼ 421.06K |
| Goldman Sachs Group Inc | 7.04M | ▲ 1.57M |
| Vanguard Fiduciary Trust Co | 6.51M | ▲ 57.90K |
| Blackrock, Inc. | 5.83M | ▲ 94.90K |
| Legal & General Group PLC | 4.47M | ▼ 18.20K |
Held by 18 ETFs
Biggest fund positions in ICL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 26 | Kilstein Alegra | other | 731,707 |
| Aug 4, 26 | Alperovitz Asaf | other | 1,829,268 |
| Jun 14, 26 | Alperovitz Asaf | other | 0 |
| May 24, 26 | Kilstein Alegra | other | 0 |
| Mar 18, 26 | Perelman Uri | other | 0 |
| Mar 18, 26 | Perelman Uri | other | 0 |
| Mar 18, 26 | Doppelt Yoav | other | 0 |
| Mar 18, 26 | Doppelt Yoav | other | 0 |
| Mar 18, 26 | Kabalek Yaniv | other | 0 |
| Mar 18, 26 | Kabalek Yaniv | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICL coverage
Recent articles, reports, and earnings notes.

ICL Group (ICL): Potash Momentum vs. Leverage
ICL is benefiting from stronger potash, bromine, and specialty product momentum, but elevated leverage and weak historical earnings keep the stock in Hold territory.

ICL Group Ltd (ICL) slips on deep earnings miss analysis
ICL Group Ltd (ICL) slips after a Q3 miss, but the deeper story is mixed. Margins held, EBITDA rose, and guidance stayed intact, yet revenue fell short and soft agriculture demand, higher costs, and cautious analyst sentiment kept pressure on the stock.

ICL Group Ltd (ICL) slips on earnings misses
ICL Group Ltd (ICL) slips 1.7% after reporting earnings misses, as investors react to weaker-than-expected results and reassess the stock's near-term outlook.
Want a deeper read on ICL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
ICL Group Q3 Earnings Call Highlights
marketbeat.com · Nov 11
ICL: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 11
ICL Group Ltd (ICL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
ICL Group (ICL) Misses Q3 Earnings and Revenue Estimates
zacks.com · Nov 10
ICL Reports Third Quarter 2026 Results
businesswire.com · Nov 10
ICL Group (ICL) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com · Nov 4
Do Options Traders Know Something About ICL Group Stock We Don't?
zacks.com · Oct 28
ICL Group (NYSE:ICL) and Gulf Resources (NASDAQ:GURE) Head-To-Head Survey
defenseworld.net · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice